Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3620 - Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Eva-Maria Grischke

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

E. Grischke1, P. Neven2, Y. Lin3, P.A. Kaufman4, G.W. Sledge5

Author affiliations

  • 1 Women’s Clinic, University Clinics Tuebingen, 72076 - Tuebingen/DE
  • 2 Gynaecological Oncology / Multidisciplinary Breast Center, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 3 Oncology, Eli Lilly and Company, Indianapolis/US
  • 4 Hematology Oncology, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, 3756 - Lebanon/US
  • 5 Medical Oncology, Stanford University, Stanford/US
More

Resources

Abstract 3620

Background

Abemaciclib, a selective inhibitor of CDK4 & 6, dosed on a continuous schedule is approved for the treatment of HR+, HER2- ABC. In the intent-to-treat population, abemaciclib with fulvestrant (F) demonstrated improved progression-free survival (PFS) and objective response rate (ORR) compared to placebo (P) + F (16.4 vs 9.3 mos, HR: 0.553; P<.0000001; ORR in measurable disease 48.1 vs 21.3%; P<.001). ET resistance (ETR) were classified into primary ETR, which includes pts whose disease relapsed while receiving the first 2 years of (neo)adjuvant ET or progressed while receiving the first 6 mos of ET for ABC, and secondary ETR. Here, we compare the efficacy and safety of abemaciclib + F vs P + F in the primary and secondary ETR subgroups.

Methods

MONARCH 2 was a phase 3 randomized, double-blind, placebo-controlled study of abemaciclib + F vs P + F in pts with HR+, HER2- ABC that progressed on ET. Key eligibility criteria were previously discussed. Pts received orally administered abemaciclib 150 mg Q12H + 500 mg F (per label) or P + F. Pts were stratified by sensitivity to ET. Primary objective was investigator-assessed PFS. Secondary objectives included efficacy, safety and tolerability.

Results

169 pts (25.3%) had primary ETR and 489 pts (73.1%) had secondary ETR. Key efficacy endpoints are summarized (Table). The most frequent adverse events in primary and secondary ETR population are similar. For primary ETR, abemaciclib + F vs P + F were diarrhea (87.3 vs 22.4%), neutropenia (43.6 vs 5.2%), nausea (41.8 vs 25.9%), abdominal pain (36.4 vs 13.8%), and anemia (31.8 vs 5.2%), respectively.Table: 329P

Summary of PFS and ORR in primary and secondary ETR population

Primary ResistanceSecondary Resistance
Abemacilib + FPlacebo + FAbemacilib + FPlacebo + F
PFS
Median (months)15.37.916.69.6
Hazard Ratio [HR] (95% CI)0.45 (0.31, 0.67)0.59 (0.46, 0.75)
Pvalue<.001<.001
ORR in measurable disease, (%)53.917.946.222.6
Pvalue<.001<.001

Conclusions

Abemaciclib + F improved PFS and ORR in pts with primary and secondary ETR, and had a generally tolerable safety profile. Although pts with primary ETR typically have poor prognosis the benefit for abemaciclib + F was maintained in pts HR+, HER2- ABC.

Clinical trial identification

NCT02107703.

Legal entity responsible for the study

Eli Lilly and Company.

Funding

Eli Lilly and Company.

Editorial Acknowledgement

Disclosure

Y. Lin: Employee and stakeholder: Eli Lilly and Company. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.